The vitamin D 25-OH total immunoassay is the standard blood test used to check your vitamin D status. It measures the combined amount of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 circulating in your blood, which together represent the body’s vitamin D stores from both dietary sources and sun exposure. While the test is widely available and reasonably reliable, the immunoassay approach has specific quirks and limitations that can affect results, and understanding those helps you interpret what the numbers on your lab report actually mean.
Why Labs Measure 25-Hydroxyvitamin D
Vitamin D goes through two chemical transformations in the body before it becomes active. The first happens in the liver, where vitamin D is converted into 25-hydroxyvitamin D, often written as 25(OH)D. The second happens in the kidneys, producing the fully active hormone 1,25-dihydroxyvitamin D. You might assume the active form would be the better thing to measure, but 25(OH)D is actually the far superior marker of your overall vitamin D stores. It stays in the blood much longer, its levels directly reflect how much vitamin D you’re getting from food, supplements, and sunlight, and it responds predictably when your intake changes.1PubMed Central. 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population The active form, 1,25(OH)2D, is tightly regulated by other hormones and can appear normal even when your vitamin D stores are severely depleted, which makes it useless for routine screening.
The Endocrine Society’s clinical guidelines explicitly recommend measuring 25(OH)D and recommend against using 1,25(OH)2D for evaluating vitamin D status, reserving the active-hormone test for specific conditions involving calcium or phosphate metabolism disorders.2The Journal of Clinical Endocrinology & Metabolism. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline A systematic review of functional markers confirmed that 25(OH)D consistently responds to improved vitamin D intake across diverse population groups, reinforcing the consensus around its use.3The American Journal of Clinical Nutrition. Existing and potentially novel functional markers of vitamin D status: a systematic review
The “total” part of the test name means it measures both the D2 and D3 forms of 25-hydroxyvitamin D together. Vitamin D2 comes primarily from plant and fungal sources, while D3 comes from animal sources and from your skin’s response to ultraviolet light.4PubMed Central. Differences in the absorption and metabolism of vitamin D2, vitamin D3, and 25 hydroxyvitamin D Both contribute to your usable vitamin D stores, so a total measurement gives a more complete picture than measuring either one alone.
How the Immunoassay Actually Works
The “IA” in the test name stands for immunoassay, which is the detection technology. There are several competing automated platforms on the market, and they don’t all work the same way under the hood. Most use a competitive approach: a labeled version of 25(OH)D is mixed with your blood sample, and both compete for binding sites on either an antibody or a protein. The less vitamin D in your blood, the more labeled molecules bind, and the machine reads that signal to calculate your level. The Roche Elecsys system, for example, uses a recombinant vitamin D binding protein as its capture molecule, while the DiaSorin LIAISON uses an antibody.5Practical Laboratory Medicine. Serum 25-hydroxyvitamin D measurement: Comparative evaluation of three automated immunoassays
A less common approach is the sandwich (non-competitive) immunoassay, used by the Fujirebio Lumipulse platform. Instead of competition, two antibodies lock onto the 25(OH)D molecule from different sides, forming a “sandwich.” The signal increases rather than decreases with higher concentrations of vitamin D. These different detection mechanisms are one reason results can differ between platforms, even when the same blood sample is tested.
The appeal of immunoassays for clinical labs is practical. When automated 25(OH)D assays first became available, they brought vitamin D testing within reach of any routine clinical chemistry lab with a standard analyzer, replacing older methods that required radioactive tracers or complex manual extraction steps.6PubMed. Hydroxyvitamin D assays: An historical perspective from DEQAS The speed, volume capacity, and relatively low per-test cost of modern automated immunoassays are the main reasons they dominate routine clinical testing worldwide.
The Gold Standard and How Immunoassays Compare
Liquid chromatography-tandem mass spectrometry, usually shortened to LC-MS/MS, is considered the reference method for measuring 25(OH)D. It physically separates D2 from D3 and measures each directly, with minimal interference from other molecules floating around in the blood. When researchers want to know how accurate an immunoassay is, they compare its results against LC-MS/MS on the same set of samples.
These comparisons show a consistent pattern: immunoassays generally track in the right direction, but they introduce a positive bias, meaning they tend to read higher than mass spectrometry. In one study of 150 serum samples, the LIAISON immunoassay had a mean bias of about 2.4 ng/mL above the LC-MS/MS result, while the ADVIA Centaur showed a larger bias of roughly 7.9 ng/mL.7Annals of Clinical & Laboratory Science. A Rapid and Simple Liquid-Chromatography-Tandem Mass Spectrometry Method for Measuring 25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3 in Human Serum: Comparison with Two Automated Immunoassays A broader comparison of five automated immunoassays found that concordance with mass spectrometry varied considerably by platform, with mean biases ranging from under 1 nmol/L for the best-performing assay to over 11 nmol/L for the worst.8Clinical Chemistry. State-of-the-Art Vitamin D Assays: A Comparison of Automated Immunoassays with Liquid Chromatography–Tandem Mass Spectrometry Methods
For most patients, a few nanograms per milliliter of bias won’t change clinical decisions. But for someone whose true level sits right near a diagnostic cutoff, the platform used could tip the result into a different category. That is worth keeping in mind if you get retested at a different lab or on a different machine.
The D2 Cross-Reactivity Problem
One persistent weakness of immunoassays involves vitamin D2. Most people get most of their vitamin D as D3, but prescription-strength vitamin D supplements in some countries are D2 (ergocalciferol). The immunoassay is supposed to detect both forms equally, since the test reports “total” 25(OH)D. In practice, several popular platforms badly undercount D2. An evaluation of the Centaur and Elecsys assays found that their cross-reactivity with 25(OH)D2 was only around 41 to 45 percent, meaning they detected less than half the D2 that was actually present.9Journal of Clinical Biochemistry and Nutrition. Performance evaluation of two immunoassays for 25-hydroxyvitamin D
If you’re taking a D3 supplement or getting most of your vitamin D from sunlight, this issue doesn’t matter much. But if you’re on a prescription D2 supplement, your immunoassay result could significantly underestimate your actual vitamin D status. Your doctor might see a low number and increase your dose when you don’t actually need it. If you know you’re taking D2 specifically, it’s worth asking whether the lab platform handles D2 well, or whether an LC-MS/MS test would give a clearer answer.
Epimer Interference
Another molecule that can trip up immunoassays is 3-epi-25-hydroxyvitamin D3, a naturally occurring mirror-image variant of 25(OH)D3. It circulates in everyone’s blood at low levels and appears in higher concentrations in infants. The problem is that some immunoassays can’t tell the epimer apart from the “real” 25(OH)D3, which inflates the reported total.
A large external quality assessment involving 445 laboratories dramatically illustrated this. When labs analyzed a normal serum sample, results were consistent, with a trimmed mean of about 45.6 nmol/L. But when labs tested a sample spiked with 50 nmol/L of the epimer, the variability between labs exploded, and the mean jumped to 62.1 nmol/L. The Roche Gen III assay showed about 91 percent cross-reactivity with the epimer, and the Beckman DxI showed roughly 40 percent, while most other immunoassays barely detected it at all.10PubMed. 3-Epimer-25-hydroxyvitamin D3 interference in assays for the measurement of 25-hydroxyvitamin D3 Other vitamin D metabolites can also cross-react. In spiked samples, the cross-reactivity of certain dihydroxyvitamin D metabolites varied wildly across different assay types, from negligible to several hundred percent in some older binding assays.11PubMed. 25-Hydroxyvitamin D assays: Potential interference from other circulating vitamin D metabolites
LC-MS/MS methods that include a chromatographic separation step can cleanly separate the epimer from 25(OH)D3. But not all mass spectrometry methods do this either. Methods without that separation step showed inflated values on epimer-spiked samples just like some immunoassays did.12PubMed Central. Multicenter comparison of analytical interferences of 25-OH vitamin D immunoassay and mass spectrometry methods by endogenous interferents and cross-reactivity with 3-epi-25-OH-vitamin D3 So mass spectrometry is not automatically immune to this issue.
Biotin and Vitamin D Binding Protein
Two other common interferences deserve attention. The first is biotin, a B vitamin found in many hair, skin, and nail supplements. Some immunoassay platforms, particularly those using a biotin-streptavidin detection system, are vulnerable to biotin in the blood. In patients taking high-dose biotin supplements, two assays (the IDS-iSYS and Roche Total 25OHD) produced dramatically inflated results, with reported values more than double the true concentration.13PubMed. Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin d (25OHD) assays When the biotin interference was neutralized in one study, the Roche assay’s median 25(OH)D reading dropped from about 90 ng/mL to 29 ng/mL, a threefold drop that would completely change a patient’s clinical picture.14PubMed. Serum biotin interference: A troublemaker in hormone immunoassays If you take any supplement containing biotin, mention it before your blood draw. Many labs now advise stopping biotin supplements 24 to 72 hours before testing.
The second interference involves vitamin D binding protein (DBP), which carries most of the 25(OH)D in your blood. DBP levels naturally vary between people and change in certain conditions. Pregnancy raises DBP levels, while kidney disease and critical illness tend to lower them. In a study examining multiple automated assays, four out of five showed an inverse relationship between DBP concentration and measurement accuracy, meaning they overestimated vitamin D when DBP was low and underestimated it when DBP was high.15Clinical Chemistry. Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration One specific platform evaluation found the DBP-related bias remained within a clinically acceptable range even in pregnant and hemodialysis patients, though the bias was notably larger than in healthy subjects.16PubMed Central. Influence of Vitamin D Binding Protein on Accuracy of 25-Hydroxyvitamin D Measurement Using the ADVIA Centaur Vitamin D Total Assay
Common substances in blood like hemoglobin from broken red blood cells, bilirubin from liver processing, and lipids from a recent meal generally don’t cause problems at typical levels. One platform evaluation showed no meaningful interference up to hemolysis and lipemia indices of 500, covering all but the most severely compromised samples.17The Journal of Applied Laboratory Medicine. Evaluation of a New Generation Automated Assay for 25-Hydroxy Vitamin D Based on Competitive Protein Binding
The Push for Standardization
The variability between immunoassay platforms created a real problem for public health: two labs could test the same person’s blood and get meaningfully different results. To address this, the Vitamin D Standardization Program (VDSP) was created, coordinating between the National Institutes of Health, the CDC, and international partners. The VDSP developed reference materials and target values tied to a gold-standard mass spectrometry method, then evaluated how well various commercial assays measured up.
An interlaboratory comparison study run by the VDSP had 15 different laboratories test 50 donor serum samples using both immunoassays and mass spectrometry methods.18Journal of AOAC INTERNATIONAL. Baseline Assessment of 25-Hydroxyvitamin D Assay Performance: A Vitamin D Standardization Program (VDSP) Interlaboratory Comparison Study A follow-up evaluation of 32 ligand binding assays across 17 laboratories found that only half of the assays met the VDSP’s accuracy target of a mean bias within 5 percent. Among 13 unique assay designs, only 4 consistently stayed within that target regardless of which lab ran them, while another 4 consistently fell outside it.19PubMed Central. Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) Intercomparison Study 2 – Part 2 ligand binding assays – impact of 25-hydroxyvitamin D2 and 24R,25-dihydroxyvitamin D3 on assay performance
The good news is that standardization efforts have measurably improved things. After calibrating immunoassay results to an LC-MS/MS reference, assay regression slopes approached 1.0 with intercepts below 0.5 ng/mL, meaning the mathematical correction effectively eliminated systematic error.20PubMed. Evaluation of automated immunoassays for 25(OH)-vitamin D determination in different critical populations before and after standardization of the assays So even if the raw signal from an immunoassay is imperfect, proper calibration can bring it in line with reference methods. A comprehensive intralaboratory evaluation by the VDSP tested 13 assays head-to-head in a single lab to isolate assay-to-assay variability from lab-to-lab variability, providing manufacturers with actionable data about where their platforms stood.21PubMed Central. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias
What the Numbers on Your Lab Report Mean
Guidelines from the Endocrine Society define vitamin D deficiency as a 25(OH)D level below 20 ng/mL (50 nmol/L) and insufficiency as 21 to 29 ng/mL (52.5 to 72.5 nmol/L).22The Journal of Clinical Endocrinology & Metabolism. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline Some pediatric guidelines use a slightly lower threshold, classifying deficiency below 15 ng/mL and severe deficiency below 5 ng/mL.23PubMed. Vitamin D deficiency in childhood-a review of current guidelines on diagnosis and management These cutoffs were established by expert panels weighing evidence about bone health, calcium absorption, and parathyroid hormone responses.
Given the assay variability described above, these cutoffs carry more uncertainty than they appear to. A result of 19 ng/mL on one platform might read as 22 ng/mL on another, pushing the same person from “deficient” to “insufficient.” Clinicians who manage vitamin D patients regularly know this and tend to treat the trend in your numbers over time, ideally measured on the same platform, rather than treating any single result as a hard boundary. If you’re borderline on a routine screening, it’s more useful to look at your overall risk factors, symptoms, and diet than to fixate on whether you’re a couple of nanograms above or below a line.
When Mass Spectrometry Makes More Sense
For most routine clinical purposes, an immunoassay gives you a good-enough number to guide supplementation decisions. But certain situations call for the higher specificity of LC-MS/MS. If you’re taking vitamin D2 supplements, as discussed earlier, mass spectrometry can separately quantify D2 and D3, sidestepping the cross-reactivity issue entirely. In research settings where precise population-level data matters, or when evaluating patients with unusual vitamin D metabolism, the reference method is preferred.
Automated LC-MS/MS systems designed for clinical lab use have recently entered the market, aiming to bridge the gap between the accuracy of mass spectrometry and the convenience of immunoassays. One such system showed a median bias of about 6.6 percent when compared against an immunoassay for 25-OH vitamin D3, which was within acceptable limits.24PubMed Central. Automated LC-MS/MS: Ready for the clinical routine Laboratory? As these systems mature and become more cost-effective, they may eventually replace immunoassays in some labs, though high-throughput immunoassay analyzers will likely remain the workhorses for large-volume routine testing for the foreseeable future.
Bioavailable and Free 25(OH)D
Most of the 25(OH)D in your blood is bound to vitamin D binding protein, with a smaller fraction bound loosely to albumin and a tiny fraction floating free. Some researchers have proposed that measuring “bioavailable” 25(OH)D (the albumin-bound plus free portions) or “free” 25(OH)D might better reflect what your tissues actually have access to, especially in conditions where binding protein levels are abnormal.
In healthy children, one study found that bioavailable and free 25(OH)D levels predicted bone mineral content about as well as total 25(OH)D in normal-weight children, but none of the vitamin D markers were associated with bone density in overweight or obese children.25PLOS ONE. Total, bioavailable and free 25-hydroxyvitamin D levels as functional indicators for bone parameters in healthy children A large population-based study of older adults found that total, bioavailable, and free 25(OH)D all showed very similar inverse associations with mortality risk, suggesting that at the population level, total 25(OH)D captures the relevant information just as effectively.26PubMed. Vitamin D-binding protein, total, “nonbioavailable,” bioavailable, and free 25-hydroxyvitamin D, and mortality in a large population-based cohort of older adults
For now, these alternative measurements remain primarily research tools. The total 25(OH)D immunoassay remains the practical clinical standard, and you’re unlikely to encounter the free or bioavailable version on a routine lab order. But if you have a condition that substantially alters your binding protein levels and your total 25(OH)D results seem to conflict with your clinical picture, your doctor might factor in binding protein status or consider a specialized test.
Practical Tips for Getting Reliable Results
Given everything above, a few straightforward steps can help ensure your vitamin D test result is as accurate as possible:
- Disclose supplements: Tell your doctor about any biotin-containing supplement before your blood draw. Hair, skin, and nail formulas often contain high-dose biotin that can dramatically inflate results on certain platforms.
- Stick with one lab: If you’re tracking your vitamin D level over time, try to use the same laboratory and platform for each test. Comparing numbers across different assay systems introduces noise that has nothing to do with your actual vitamin D status.
- Mention D2 supplementation: If you’re on prescription ergocalciferol (vitamin D2), make sure your provider knows, since some immunoassays undercount D2 significantly.
- Don’t sweat borderline values: A result of 19 versus 21 ng/mL could easily be assay variability rather than a true clinical difference. Decisions about supplementation should weigh your overall context, not a single number sitting near a cutoff.
Vitamin D testing has come a long way since the days of manual radioimmunoassays, and standardization programs have steadily closed the gap between platforms. The total 25(OH)D immunoassay you’ll encounter at most clinical labs is a good, practical tool for assessing and monitoring your vitamin D status. Its imperfections are real but manageable when both you and your clinician know where they come from.